Keywords: gilead, sciences, revenues, fell, million, net, loss
Gilead Sciences' revenues
Article | 10 February 1999
fell 18.6% to $32.6 million in 1998 while net loss more than doubled to$56.1 million. Revenues were driven primarily by Vistide (cidofovir injection), ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
